Table 1.

Molecular landascape in lung cancer associated to diverse histotypes.

Histotype		Type of genomic aberrations	Gene		Frequency (%)	Currently available Target therapy	Ref.
NSCLC	ADC	Fusions	ALK		3-7	A	46
			ROS1		2-3	A	47
			RET		1-2	NA	47
			NTRK1		1-2	NA	48
		Mutations	EGFR		30-40	A	49
			BRAF		0.5-5	NA	47
			KRAS		20-30	NA	47
			MET		3-4	NA	50
			PTEN		1.7	NA	51
			PDGFRA		6-7	NA	52
			PIK3CA		5	NA	53, 54
			TP53		52	NA	55
		Copy number gene alterations	Gains	ERBB2	2-5	NA	56
				EGFR	10	NA	57
				MET	2-5	NA	50
				TERT	75	NA	58
			Losses	CDKN2A	7	NA	59
	SqCCs	Fusions		FGFRs	23	NA	60
		Mutations		TP53	79	NA	55
				NF1	10	NA	52
				FGFR1	20	NA	60
				FGFR2	3	NA	61
				DDR2	2-3	NA	62
				BRAF	4-5	NA	63
				KRAS	1-2	NA	64
				PDGFRA	4	NA	52
				PIK3CA	15	NA	53, 54
				PTEN	10	NA	51
		Copy number gene alterations	Gains	SOX2	65	NA	65
				PIK3CA	15	NA	53, 54
				TP53	79	NA	55
			Losses	CDKN2A	15	NA	59
				PTEN	8	NA	66
SCLC		Mutations		TP53	90	NA	67, 68
				RB1	90	NA	67, 68
				EP300	4-6	NA	69, 70
				CREBBP	4-6	NA	69, 70
				PTEN	10-18	NA	68
		Copy number gene alterations	Gains	MYC	20-30	NA	71
				MYCN	20-30	NA	71
				MYCL1	20-30	NA	71
				SOX2	27	NA	72
				FGFR1	5-6	NA	73